I wasn't suggesting saying the opposite... (although if there is persistent/reactivated virus then antivirals may well be helpful to some). It just seems that the press have gone out of their way to get positive quotes about this study, particularly from those who are supported by the patient community, and yet there are so many obvious caveats.
Also, it seems that is precisely what this paper does do (giving "a huge amount of rope to private physicians selling toxic medications like antivirals etc"). The unqualified suggestion that there is "persistent antigen" that requires removal is just the sort of thing that quack physicians will be leaping all over.
You've already acknowledged earlier in this thread that use of checkpoint inhibitors could well be counterproductive. I would agree. Taking the brakes off a system that could well lead to autoimmunity doesn't seem terribly sensible. The data on which this is based is sketchy at best - the PD-1 CD8+ subgroup data are poor and the analysis suspect (just look at the scatter graph and overlap - comparing means in that context seems somewhat meaningless).
If they do test this in a combination therapy trial (CBT/GET + CI + something else (Ampligen?)), as suggested at the end of the discussion, it looks like it is set up to fail. An opportunity to say, "see, it was deconditioning all along" maybe? Where have we seen that before?
I think what is happening at NIH is similar to what happened with PACE - a need to appease competing theories: in PACE it was White's GET vs Sharpe's CBT; in NIH, it's Walitt's Effort Preference deconditioning theory vs Nath's (?) persistent antigen leading to immune dysfunction theory, with a sprinkling of central mechanisms to tie the two together.
Mashing these theories together seems to be done more to favour the researchers than to do anything to find a valid treatment path for patients.